Evidence Synthesis Planning Tactic
Plan the complete statistical synthesis approach: effect size standardization, model selection, heterogeneity quantification, sensitivity analyses, and PRISMA-compliant reporting.
Stages
Stage 1: Effect Size Type Determination
Determine the appropriate effect size metric for the synthesis.
| Outcome Type |
Effect Size |
When |
| Continuous (same scale) |
Mean Difference (MD) |
All studies use same measurement |
| Continuous (different scales) |
Standardized Mean Difference (SMD) |
Studies use different instruments |
| Binary |
Odds Ratio (OR) / Risk Ratio (RR) |
Dichotomous outcomes |
| Time-to-event |
Hazard Ratio (HR) |
Survival data |
| Correlation |
Fisher's z (transformed r) |
Association studies |
| Count/rate |
Incidence Rate Ratio (IRR) |
Event rate data |
SOPs: effect-size-planning
Stage 2: Model Selection
Choose between fixed-effect and random-effects models.
- Fixed-effect (Mantel-Haenszel, Inverse Variance): assumes one true effect, studies estimate same parameter
- Random-effects (DerSimonian-Laird, REML, Paule-Mandel, Knapp-Hartung): assumes distribution of true effects
- Decision criteria: clinical/methodological diversity, number of studies, intended inference scope
- Knapp-Hartung adjustment: recommended when k < 20 studies
Decision tree: If studies are clinically homogeneous AND methodologically identical → fixed-effect. Otherwise → random-effects with REML + Knapp-Hartung.
Stage 3: Heterogeneity Strategy
Plan heterogeneity quantification and investigation.
- Quantification: I2 (proportion), tau2 (absolute), H2, prediction interval
- Testing: Cochran's Q (detection), confidence intervals for I2
- Investigation: pre-specified subgroups, meta-regression (if k >= 10)
- Thresholds: I2 interpretation (0-40% low, 30-60% moderate, 50-90% substantial, 75-100% considerable)
SOPs: heterogeneity-source-analysis
Stage 4: Sensitivity Design
Design robustness checks for the primary analysis.
- Leave-one-out analysis (influence of individual studies)
- Influence diagnostics (Cook's distance, DFFITS, hat values)
- Subgroup analyses (pre-specified moderators only)
- Alternative model (fixed vs random comparison)
- Alternative effect size (OR vs RR, SMD vs MD)
- Excluding high risk-of-bias studies
SOPs: sensitivity-analysis-design
Stage 5: Reporting Plan
Design PRISMA-2020 compliant reporting.
- PRISMA flow diagram (identification, screening, eligibility, inclusion)
- Forest plot specifications (study labels, weights, diamonds)
- Summary of findings table (GRADE certainty)
- Heterogeneity reporting (I2, tau2, prediction interval)
- Sensitivity analysis presentation
- Protocol registration (PROSPERO)
Minimum Yield
Per execution of this tactic:
- Effect size type justified and documented
- Model selection with explicit rationale
- Heterogeneity quantification plan complete
- At least 3 sensitivity analyses designed
- PRISMA reporting checklist addressed
Output Format
synthesis_plan:
effect_size:
type: [SMD/OR/RR/MD/HR/z]
justification: [why this metric]
conversions_needed: [any transformations]
model:
type: [fixed-effect/random-effects]
estimator: [IV/MH/REML/DL/PM]
adjustment: [Knapp-Hartung/none]
justification: [rationale]
heterogeneity:
metrics: [I2, tau2, Q, prediction interval]
investigation:
subgroups: [list of categorical moderators]
meta_regression: [list of continuous moderators]
minimum_k_per_subgroup: [threshold]
sensitivity:
- leave_one_out
- influence_diagnostics
- alternative_model
- rob_exclusion
- [additional pre-specified]
reporting:
standard: PRISMA-2020
registration: [PROSPERO ID or plan]
grade_domains: [risk_of_bias, inconsistency, indirectness, imprecision, publication_bias]
Available SOPs
Optional, no fixed order; the final leaf is always a sop.
| SOP |
When to use |
| effect-size-planning |
Determine effect size types and calculation methods for meta-analytic synthesis |
| heterogeneity-source-analysis |
Identify and classify sources of between-study heterogeneity (clinical, methodological, statistical) |
| sensitivity-analysis-design |
Design leave-one-out, influence diagnostics, subgroup analyses, and robustness checks |
1---2name: evidence-synthesis-planning3description: Plan the statistical synthesis approach — model selection, heterogeneity strategy, and reporting4---56# Evidence Synthesis Planning Tactic78Plan the complete statistical synthesis approach: effect size standardization, model selection, heterogeneity quantification, sensitivity analyses, and PRISMA-compliant reporting.910## Stages1112### Stage 1: Effect Size Type Determination1314Determine the appropriate effect size metric for the synthesis.1516| Outcome Type | Effect Size | When |17|--------------|-------------|------|18| Continuous (same scale) | Mean Difference (MD) | All studies use same measurement |19| Continuous (different scales) | Standardized Mean Difference (SMD) | Studies use different instruments |20| Binary | Odds Ratio (OR) / Risk Ratio (RR) | Dichotomous outcomes |21| Time-to-event | Hazard Ratio (HR) | Survival data |22| Correlation | Fisher's z (transformed r) | Association studies |23| Count/rate | Incidence Rate Ratio (IRR) | Event rate data |2425**SOPs**: effect-size-planning2627### Stage 2: Model Selection2829Choose between fixed-effect and random-effects models.3031- **Fixed-effect** (Mantel-Haenszel, Inverse Variance): assumes one true effect, studies estimate same parameter32- **Random-effects** (DerSimonian-Laird, REML, Paule-Mandel, Knapp-Hartung): assumes distribution of true effects33- **Decision criteria**: clinical/methodological diversity, number of studies, intended inference scope34- **Knapp-Hartung adjustment**: recommended when k < 20 studies3536**Decision tree**: If studies are clinically homogeneous AND methodologically identical → fixed-effect. Otherwise → random-effects with REML + Knapp-Hartung.3738### Stage 3: Heterogeneity Strategy3940Plan heterogeneity quantification and investigation.4142- **Quantification**: I2 (proportion), tau2 (absolute), H2, prediction interval43- **Testing**: Cochran's Q (detection), confidence intervals for I244- **Investigation**: pre-specified subgroups, meta-regression (if k >= 10)45- **Thresholds**: I2 interpretation (0-40% low, 30-60% moderate, 50-90% substantial, 75-100% considerable)4647**SOPs**: heterogeneity-source-analysis4849### Stage 4: Sensitivity Design5051Design robustness checks for the primary analysis.5253- Leave-one-out analysis (influence of individual studies)54- Influence diagnostics (Cook's distance, DFFITS, hat values)55- Subgroup analyses (pre-specified moderators only)56- Alternative model (fixed vs random comparison)57- Alternative effect size (OR vs RR, SMD vs MD)58- Excluding high risk-of-bias studies5960**SOPs**: sensitivity-analysis-design6162### Stage 5: Reporting Plan6364Design PRISMA-2020 compliant reporting.6566- PRISMA flow diagram (identification, screening, eligibility, inclusion)67- Forest plot specifications (study labels, weights, diamonds)68- Summary of findings table (GRADE certainty)69- Heterogeneity reporting (I2, tau2, prediction interval)70- Sensitivity analysis presentation71- Protocol registration (PROSPERO)7273## Minimum Yield7475Per execution of this tactic:76- Effect size type justified and documented77- Model selection with explicit rationale78- Heterogeneity quantification plan complete79- At least 3 sensitivity analyses designed80- PRISMA reporting checklist addressed8182## Output Format8384```yaml85synthesis_plan:86 effect_size:87 type: [SMD/OR/RR/MD/HR/z]88 justification: [why this metric]89 conversions_needed: [any transformations]90 model:91 type: [fixed-effect/random-effects]92 estimator: [IV/MH/REML/DL/PM]93 adjustment: [Knapp-Hartung/none]94 justification: [rationale]95 heterogeneity:96 metrics: [I2, tau2, Q, prediction interval]97 investigation:98 subgroups: [list of categorical moderators]99 meta_regression: [list of continuous moderators]100 minimum_k_per_subgroup: [threshold]101 sensitivity:102 - leave_one_out103 - influence_diagnostics104 - alternative_model105 - rob_exclusion106 - [additional pre-specified]107 reporting:108 standard: PRISMA-2020109 registration: [PROSPERO ID or plan]110 grade_domains: [risk_of_bias, inconsistency, indirectness, imprecision, publication_bias]111```112113<!-- BEGIN available-tables (generated) -->114115## Available SOPs116117Optional, no fixed order; the final leaf is always a sop.118119| SOP | When to use |120| --- | --- |121| effect-size-planning | Determine effect size types and calculation methods for meta-analytic synthesis |122| heterogeneity-source-analysis | Identify and classify sources of between-study heterogeneity (clinical, methodological, statistical) |123| sensitivity-analysis-design | Design leave-one-out, influence diagnostics, subgroup analyses, and robustness checks |124125<!-- END available-tables (generated) -->